NEXENTIS TECHNOLOGIES INC. Net Income (Loss) from Continuing Operations Available to Common Shareholders, Diluted
NEXENTIS TECHNOLOGIES INC. (NXTS) reported Net Income (Loss) from Continuing Operations Available to Common Shareholders, Diluted of -$5.87 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-31.
Financial Statements › Income Statement › Other Income
us-gaap:NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersDiluted · last filed 2026-03-31
- NEXENTIS TECHNOLOGIES INC. net income (loss) from continuing operations available to common shareholders, diluted for fiscal 2025 was -$5.87M.
| Period end | Net Income (Loss) from Continuing Operations Available to Common Shareholders, Diluted 12 month |
|---|---|
| 2025-12-31 | -$5.87M 10-K · filed 2026-03-31 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Decoy Therapeutics Inc. (DCOY) | United States | $0.002B | -0.27 |
| ORAGENICS INC (OGEN) | United States | $0.002B | |
| JUPITER NEUROSCIENCES, INC. (JUNS) | United States | $0.002B | -0.02 |
| BioXcel Therapeutics, Inc. (BTAI) | United States | $0.002B | |
| ZyVersa Therapeutics, Inc. (ZVSA) | United States | $0.002B | |
| Matinas BioPharma Holdings, Inc. (MTNB) | United States | $0.003B | |
| Petros Pharmaceuticals, Inc. (PTPI) | United States | $0.003B | |
| GeoVax Labs, Inc. (GOVX) | United States | $0.003B | -0.45 |
| Silo Pharma, Inc. (SILO) | United States | $0.003B | -1.57 |
| Genprex, Inc. (GNPX) | United States | $0.003B | -0.02 |